Dovobet

How to order Dovobet

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Dovobet on Prescriptsy

Dovobet is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Dovobet is a prescription-only topical medicine containing two active ingredients, calcipotriol 50 micrograms per gram and betamethasone dipropionate 0.5 mg per gram, used for the treatment of stable plaque psoriasis vulgaris in adults.

It is manufactured by LEO Pharma and is available in the UK as an ointment for body psoriasis and as a gel or foam formulation suitable for scalp and body application.

By combining a vitamin D analogue with a potent corticosteroid in a single product, Dovobet simplifies the treatment regimen and delivers superior plaque clearance compared with either ingredient used on its own.

Psoriasis affects approximately 1.8 million people in the United Kingdom.

Plaque psoriasis, the most common form, accounts for around 80 to 90% of cases and presents as well-defined, raised, red or pink patches covered with silvery-white scale.

The plaques most commonly appear on the elbows, knees, lower back, and scalp, although any area of the body can be affected.

The condition follows a relapsing and remitting course, with flare-ups triggered by stress, infection, skin injury, certain medications, and seasonal changes.

Psoriasis is not simply a cosmetic concern; it causes significant physical discomfort including itching, stinging, and cracking of the skin, and has a substantial impact on psychological wellbeing and quality of life.

Important safety information about Dovobet

Before using Dovobet, please note the following key safety points. Dovobet is a prescription-only medicine (POM) and should be used only as directed by your prescriber or pharmacist.

• Dovobet contains a potent corticosteroid. Treatment courses should not normally exceed 4 weeks. Prolonged or excessive use increases the risk of skin thinning, stretch marks, and visible blood vessels.
• Do not apply Dovobet to your face, flexures (skin folds), or genital area. These areas have thinner skin that is more susceptible to corticosteroid side effects.
• Do not exceed the recommended maximum daily dose of 15 g or treat more than 30% of body surface area at one time.
• Dovobet gel and foam are flammable. Avoid naked flames, smoking, and ignition sources during and immediately after application.
• If you are using other vitamin D preparations (topical or oral supplements), inform your prescriber. Excessive vitamin D exposure can raise blood calcium levels.

Understanding plaque psoriasis

Plaque psoriasis is a chronic, immune-mediated inflammatory skin disease.

In healthy skin, the epidermis renews itself approximately every 28 to 30 days as new keratinocytes form at the base and migrate to the surface, where they are shed.

In psoriasis, an overactive immune response driven primarily by T-helper 17 (Th17) cells and their cytokines, including interleukin-17, interleukin-23, and tumour necrosis factor alpha, accelerates this process dramatically.

Keratinocyte turnover increases to every 3 to 5 days, producing the thickened, scaly plaques characteristic of the disease.

The inflammatory infiltrate in psoriatic skin includes neutrophils, dendritic cells, macrophages, and T lymphocytes. Blood vessel proliferation in the dermis gives the plaques their characteristic erythematous (red) base.

This combination of rapid cell turnover, inflammation, and abnormal vascularisation is the target of Dovobet's dual-action formulation.

How Dovobet works: mechanism of action

Dovobet combines two active substances with complementary mechanisms that address different aspects of the psoriatic process.

Calcipotriol is a synthetic analogue of calcitriol (1,25-dihydroxyvitamin D3), the active form of vitamin D.

It binds to the vitamin D receptor (VDR) in keratinocytes and modulates gene transcription, inhibiting excessive cell proliferation and promoting orderly differentiation and maturation of the epidermis.

This corrects the accelerated skin turnover that produces the thick, scaly plaques of psoriasis.

Calcipotriol also has immunomodulatory properties, reducing the production of pro-inflammatory cytokines by Th1 and Th17 lymphocytes in the skin.

Betamethasone dipropionate is a potent topical corticosteroid classified as WHO group III. It exerts its anti-inflammatory effect by binding to intracellular glucocorticoid receptors and modulating gene expression.

This reduces the synthesis of inflammatory mediators including prostaglandins, leukotrienes, and cytokines, and decreases the migration and activity of inflammatory cells in the dermis and epidermis.

The clinical result is rapid reduction in redness, swelling, and itching.

The two-compound formulation produces synergistic effects. Betamethasone provides rapid symptom relief within days, while calcipotriol addresses the underlying keratinocyte dysfunction and provides sustained benefit.

Randomised controlled trials have shown that the combination achieves higher rates of complete or near-complete clearance at 4 weeks than either calcipotriol or betamethasone used as monotherapy.

Clinical evidence and UK prescribing guidance

Dovobet is supported by a robust evidence base.

Pivotal clinical trials demonstrated that once-daily application of the two-compound ointment achieved at least 75% improvement in the Psoriasis Area and Severity Index (PASI 75) in approximately 50% of patients at 4 weeks, compared with about 35% for betamethasone alone and 15% for calcipotriol alone.

Long-term studies of the intermittent use regimen (repeating 4-week courses when plaques recur) have confirmed sustained efficacy and a favourable safety profile over 52 weeks.

NICE Clinical Knowledge Summaries (CKS) on psoriasis recommend a potent corticosteroid applied once or twice daily as first-line treatment for trunk and limb plaque psoriasis, with a vitamin D analogue offered as an alternative or adjunct.

The two-compound formulation (calcipotriol/betamethasone) is specifically referenced as a convenient once-daily option that may improve adherence.

The British Association of Dermatologists (BAD) guidelines similarly endorse calcipotriol/betamethasone as a first-line topical therapy for mild to moderate plaque psoriasis.

For scalp psoriasis, Dovobet gel is recommended by NICE as a first-line treatment option. The gel and foam formulations are designed for practical application to hair-bearing skin and leave minimal residue compared with ointment.

Dovobet formulations: ointment, gel, and foam

Dovobet ointment has a greasy base suitable for dry, thick plaques on the body.

It provides excellent skin contact and hydration, making it well suited to scaly plaques on the elbows, knees, and trunk.

The ointment is the original formulation and has the longest track record of clinical use.

Dovobet gel has a lighter, non-greasy base designed for use on the scalp and body.

It spreads easily through hair and is more cosmetically acceptable than ointment for daytime use. The gel dries quickly and does not leave an oily residue on clothing.

Dovobet foam was introduced more recently and is licensed for scalp and body psoriasis.

The foam delivers the active ingredients in a vehicle that spreads easily over larger body areas and through scalp hair.

Patients often prefer the foam for its ease of application and rapid absorption.

All three formulations contain the same concentrations of calcipotriol and betamethasone and share the same dosing regimen of once-daily application for up to 4 weeks.

How to use Dovobet

Apply Dovobet once daily to affected areas of skin. For ointment and gel, apply a thin layer to each plaque and rub in gently.

For foam, dispense a small amount onto a clean surface or directly onto the affected area and spread evenly.

Wash your hands thoroughly after application unless the hands are the treatment area.

Apply emollients (moisturisers) at a different time of day from Dovobet to avoid diluting or removing the active treatment.

A good approach is to apply Dovobet in the evening and use an emollient in the morning, or vice versa. Allow at least 30 minutes between applications.

Do not exceed 15 g per day. As a guide, one fingertip unit (approximately 0.5 g) covers an area of skin roughly the size of two adult palms.

Do not treat more than 30% of body surface area. If your psoriasis is extensive, your prescriber may need to consider alternative or additional treatments.

Do not bandage or cover the treated area with occlusive dressings unless your dermatologist specifically advises this. Occlusion increases corticosteroid absorption and the risk of local and systemic side effects.

Side effects of Dovobet

Common side effects

The most frequently reported side effects are local reactions at the application site, including mild burning or stinging on initial application, itching (pruritus), and skin irritation.

These effects are generally mild, tend to occur at the start of treatment, and usually settle within the first week as the skin adjusts.

Uncommon side effects

Less frequently reported effects include folliculitis (inflamed hair follicles presenting as small red bumps), skin thinning (atrophy) at the application site, stretch marks (striae), visible small blood vessels (telangiectasia), and contact dermatitis.

These are more likely with prolonged or excessive use, particularly if the product is applied to flexural skin or used under occlusion.

Rare side effects

Excessive use of calcipotriol beyond recommended doses may cause hypercalcaemia (raised blood calcium). Symptoms include nausea, vomiting, abdominal pain, constipation, excessive thirst, frequent urination, muscle weakness, and confusion.

If these symptoms occur, stop using Dovobet and seek medical advice promptly.

Systemic absorption of betamethasone can rarely cause adrenal suppression, features of Cushing syndrome, or elevated blood glucose if used excessively or over very large areas.

Allergic contact dermatitis is rare. If you develop worsening redness, vesicles (small blisters), or marked swelling at the application site, discontinue use and consult your GP.

When to seek medical advice

Contact your GP or pharmacist if local side effects are persistent or troublesome. Seek urgent advice if you develop symptoms suggesting hypercalcaemia or a severe allergic reaction.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Treatment duration and skin thinning

Because Dovobet contains a potent corticosteroid, treatment courses should be limited to 4 weeks. Repeated courses are acceptable with treatment-free intervals, but continuous uninterrupted use is not recommended.

Prolonged corticosteroid use causes atrophy (thinning) of the skin, striae (stretch marks), easy bruising, and telangiectasia. These changes may be irreversible.

If your psoriasis requires frequent retreatment, your prescriber should consider stepping down to a milder corticosteroid or calcipotriol alone for maintenance, or referral for specialist assessment.

Areas to avoid

Do not apply Dovobet to the face, eyes, mouth, or genitals. Facial skin is thin and particularly vulnerable to corticosteroid-induced atrophy.

Do not use in flexural areas (groin, armpits, under breasts) unless specifically directed by your dermatologist, as absorption is increased in skin folds.

If scalp psoriasis extends onto the face or ears, use the product only on the scalp and ask your prescriber about a suitable alternative for adjacent facial skin.

Calcium metabolism

Calcipotriol can increase serum calcium, particularly if used in excessive quantities. Avoid using Dovobet concurrently with other topical or oral vitamin D preparations without medical supervision.

Patients with renal impairment are at higher risk of hypercalcaemia and should have serum calcium monitored if using calcipotriol-containing products.

Pregnancy and breastfeeding

The safety of Dovobet in pregnancy has not been fully established.

Both calcipotriol and betamethasone should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus.

Topical corticosteroids used in pregnancy in high doses or over large areas have been associated with low birth weight.

If you are pregnant, planning to become pregnant, or breastfeeding, discuss alternative treatment options with your prescriber.

Dovobet compared with other psoriasis treatments

Several topical options are available for plaque psoriasis in the UK.

Calcipotriol (Dovonex) alone is a suitable first-line alternative for patients who prefer to avoid corticosteroids or who require long-term maintenance therapy, as it does not carry the risk of skin thinning.

Coal tar preparations remain available but are cosmetically less acceptable and less commonly prescribed. Dithranol (anthralin) is effective but can stain skin and clothing.

Potent corticosteroid monotherapy (such as betamethasone valerate or mometasone) provides rapid symptom relief but carries the same risk of skin thinning as the corticosteroid component in Dovobet.

For moderate to severe psoriasis that does not respond adequately to topical treatment, NHS pathways include phototherapy (narrowband UVB), systemic therapies (methotrexate, ciclosporin, acitretin), and biologic medicines (such as adalimumab, secukinumab, and guselkumab).

A dermatology referral is appropriate if topical treatments including Dovobet fail to provide adequate control.

Living with plaque psoriasis: practical advice

Regular use of emollients is a cornerstone of psoriasis management. Apply a fragrance-free, unperfumed emollient liberally at least twice daily, separate from your Dovobet application.

This keeps the skin hydrated, reduces scale, and helps prevent cracking. Emollients are available free of charge on NHS prescription.

Avoid known triggers where possible.

Common triggers include stress, throat infections (streptococcal), skin injury (the Koebner phenomenon), smoking, excess alcohol, and certain medications such as lithium, beta-blockers, and antimalarials.

If you notice consistent triggers, discuss these with your GP or dermatologist.

Psoriasis can significantly affect mental health. If you are experiencing low mood, anxiety, or reduced confidence due to your skin condition, support is available through your GP, the NHS psychological therapies service (IAPT), and charities including the Psoriasis Association (psoriasis-association.org.uk).

How to get a Dovobet prescription in the UK

Dovobet is a prescription-only medicine available through the NHS. Your GP can prescribe it following a clinical assessment of your psoriasis.

If your psoriasis is moderate to severe, difficult to control, or affecting sensitive areas, your GP may refer you to a dermatologist for specialist management.

Authorised online prescribers registered with the General Pharmaceutical Council (GPhC) may also prescribe Dovobet following a structured consultation.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Dovobet is also available from community pharmacies on private prescription.

Sources

• Dovobet Ointment, Summary of Product Characteristics (EMC)
• Calcipotriol with betamethasone, British National Formulary (BNF)
• NICE CKS: Psoriasis
• Psoriasis, NHS
• British Association of Dermatologists, Psoriasis
• MHRA Yellow Card Scheme